Cargando…
Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis
BACKGROUND: More than a third of thyroid carcinoma (TC) patients require treatment with radioactive iodine (RAI), but the timing of initial RAI therapy after thyroidectomy remains controversial. METHODS: We included 1224 differentiated thyroid carcinoma (DTC) patients during 2015–2019, divided them...
Autores principales: | Cheng, Fang, Xiao, Juan, Huang, Fengyan, Shao, Chunchun, Ding, Shouluan, Yun, Canhua, Jia, Hongying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189474/ https://www.ncbi.nlm.nih.gov/pubmed/35179295 http://dx.doi.org/10.1002/cam4.4607 |
Ejemplares similares
-
A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
por: Xiao, Juan, et al.
Publicado: (2021) -
Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine
por: Yun, Canhua, et al.
Publicado: (2021) -
Preablative Stimulated Thyroglobulin and Thyroglobulin Reduction Index as Decision-Making Markers for Second Radioactive Iodine Therapy in Patients with Structural Incomplete Response
por: Wang, Lihua, et al.
Publicado: (2021) -
Association of the Cumulative Dose of Radioactive Iodine Therapy With Overall Survival in Patients With Differentiated Thyroid Cancer and Pulmonary Metastases
por: Yang, Jing, et al.
Publicado: (2019) -
Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival
por: Jannin, Arnaud, et al.
Publicado: (2022)